BFM
IMVT icon

Boothbay Fund Management’s Immunovant IMVT Stock Holding History

Boothbay Fund Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-124,900
Closed -$2.13M – 1608
2025
Q1 		$2.13M Buy
+124,900
New +$2.61M 0.06% 406
2024
Q1 		– Sell
-35,400
Closed -$1.49M – 1742
2023
Q4 		$1.49M Sell
35,400
-80,100
-69% -$2.95M 0.04% 592
2023
Q3 		$4.43M Buy
115,500
+100,300
+660% +$2.27M 0.11% 247
2023
Q2 		$288K Buy
+15,200
New +$283K 0.01% 1322
2021
Q3 		– Sell
-26,500
Closed -$280K – 2037
2021
Q2 		$280K Buy
26,500
+26,229
+9,679% +$366K 0.01% 1326
2021
Q1 		$435K Buy
+271
New +$7.15K 0.02% 1010

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Boothbay Fund Management's IMVT Position: Q3 2024 in Review

Boothbay Fund Management sold out of Immunovant (IMVT) in Q3 2024, closing a stake of 64,796 shares — an estimated $1.91M sold.

Boothbay Fund Management first reported a position in IMVT in Q3 2019 and held it in 15 quarters. The position peaked at $4.33M in Q3 2019. 181 funds tracked by Wall St. Rank hold IMVT as of Q3 2024.

  • Boothbay Fund Management reported no remaining Immunovant position as of Q3 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 64,796 Immunovant shares in Q3 2024, an estimated $1.91M.
  • Boothbay Fund Management first reported a position in Immunovant in Q3 2019 and held it in 15 quarters.
  • Boothbay Fund Management's Immunovant position peaked at $4.33M in Q3 2019.
  • 181 funds tracked by Wall St. Rank held Immunovant as of Q3 2024.

Based on Boothbay Fund Management's 13F filing for Q3 2024, filed 14 Nov 2024.